Loading clinical trials...
Loading clinical trials...
To evaluate the efficacy and safety of treatment with SK-1403 for 24 weeks in patients with secondary hyperparathyroidism on maintenance hemodialysis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sanwa Kagaku Kenkyusho Co., Ltd.
NCT03969329 · Secondary Hyperparathyroidism
NCT03633708 · Secondary Hyperparathyroidism, Chronic Kidney Disease
NCT07122401 · Secondary Hyperparathyroidism, Chronic Kidney Disease
NCT06126016 · Chronic Kidney Disease 5D, Secondary Hyperparathyroidism
NCT04922892 · Secondary Hyperparathyroidism;Parathyroidectomy
Investigational site (there may be other sites in this country)
Tokyo
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions